close
Add to watchlist
Salix Pharmaceuticals Ltd (SLXP) Healthcare, Biotechnology & Drugs
Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs used in the treatment of gastrointestinal disorders in the United States. Its products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. The company also offers Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; Apriso, for the maintenance of remission of ulcerative colitis in adults; and Colazal capsules for the treatment of ulcerative colitis. Salix Pharmaceuticals’ products under development include Balsalazide Disodium tablets for ulcerative colitis; Crofelemer for HIV-associated diarrhea; Vapreotide acetate for acute esophageal variceal bleeding; and Metoclopramide-Zydis for the treatment of gastroesphageal reflux and gastroparesis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars—Sinai Medical Center; ALW Partnership; Debiopharm Group; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 50.99 |
| Volume | (mio) 1.94 |
| Volume Avg | 852107 |
| 52 Week High | 51.37 |
| 52 Week Low | 25.64 |
| PE | 35.45 |
| PE (group average) | 39 |
| EPS Year | 1.44 |
| EPS change Q/Q | 100% |
| EPS change Q/Q Yr ago | -100% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -2500% |
| REV change Q/Q | -10.63% |
| REV change Q/Q Yr ago | 140.14% |
| EPS next Q est | 0.63 |
| EPS next Y est | 3.04 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |